Alto Neuroscience/$ANRO

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Alto Neuroscience

Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals' neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.

Ticker

$ANRO
Sector
Health

Primary listing

NYSE

Employees

76
Headquarters
Mountain View, United States
Website
www.altoneuroscience.com

ANRO Metrics

BasicAdvanced
$384M
-
-$2.40
-
-

What the Analysts think about ANRO

Analyst ratings (Buy, Hold, Sell) for Alto Neuroscience stock.

Bulls say / Bears say

Alto secured $50 million in an at-the-market PIPE led by Perceptive Advisors, extending its liquidity runway into 2028 to fund ALTO-207 Phase 2b and Phase 3 development. (Business Wire)
Acquisition of ALTO-207 (formerly CTC-501) adds a late-stage dopamine agonist combination with robust Phase 2a MADRS efficacy (Cohen’s d = 1.1) and positions Alto for a potentially pivotal mid-2026 trial in treatment-resistant depression. (Business Wire)
A successful FDA meeting de-risks the regulatory path for ALTO-207 by securing alignment on study design and enabling accelerated development timelines toward Phase 2b and Phase 3 trials. (Business Wire)
Alto remains pre-revenue with no commercial products, relying on successive financings to sustain operations. This may pressure dilution and financial health. (TipRanks)
The pivotal potential of ALTO-207 hinges on data from a small Phase 2a trial of only 32 patients, raising the risk that larger Phase 2b/3 studies may not replicate early efficacy or tolerability. (Business Wire)
The issuance of approximately 3.8 million shares and up to 4.6 million pre-funded warrants in the recent PIPE could significantly dilute existing shareholders, limiting upside per share unless there is substantial share price appreciation. (Business Wire)
Data summarised monthly by Lightyear AI. Last updated on 30 Oct 2025.

ANRO Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

ANRO News

AllArticlesVideos
Alto Neuroscience to Participate in Upcoming Investor Conferences

Alto Neuroscience to Participate in Upcoming Investor Conferences

Business Wire4 days ago
Alto Neuroscience Announces Plans to Accelerate Development of ALTO-207 in Treatment Resistant Depression Following Successful Outcome from Recent FDA Meeting

Alto Neuroscience Announces Plans to Accelerate Development of ALTO-207 in Treatment Resistant Depression Following Successful Outcome from Recent FDA Meeting

Business Wire2 weeks ago
Alto Neuroscience Announces $50 Million Private Placement Financing

Alto Neuroscience Announces $50 Million Private Placement Financing

Business Wire2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ANRO

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs